Valuation : Axsome Therapeutics, Inc.

Market Cap 1.08TCr 932.33Cr 875.83Cr 800.69Cr 1.5TCr 1,02300Cr 1.5TCr 10TCr 4.01TCr 52TCr 4.06TCr 3.98TCr 1,69100Cr P/E 2026 *
-77.3x
P/E 2027 * 44.9x
Enterprise Value 1.07TCr 918.86Cr 863.17Cr 789.11Cr 1.48TCr 1,00800Cr 1.48TCr 10TCr 3.96TCr 52TCr 4.01TCr 3.92TCr 1,66700Cr EV / Sales 2026 *
11x
EV / Sales 2027 * 6.65x
Free-Float
84.69%
Yield 2026 *
-
Yield 2027 * -
1 day-0.80%
1 week+3.85%
Current month+4.11%
1 month-2.59%
3 months-10.71%
6 months+25.96%
Current year+13.16%
1 week 197.05
Extreme 197.0501
210.59
1 month 197.05
Extreme 197.0501
223.4
Current year 152.28
Extreme 152.28
260.19
1 year 112.9
Extreme 112.9
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 20.63
Extreme 20.63
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 12/01/2012
Director of Finance/CFO 51 16/05/2018
Chief Operating Officer 42 01/04/2014
Director TitleAgeSince
Chairman 57 12/01/2012
Director/Board Member 64 01/12/2014
Director/Board Member 58 01/12/2014
Date Insider Type Main position Quantity % Market Cap. Importance
03/09/26 Exercice

Chief Operating Officer

30,000 0.0583%
06/08/26 Exercice

Chief Executive Officer

13,980 0.0272%
01/07/26 Exercice

Chief Executive Officer

1,48,998 0.2895%
Change 5-day change 1-year change 3-year change Capi.($)
-0.80%+3.85%+66.13%+153.01% 1.08TCr
-1.87%+4.22%+45.93%-0.47% 8.27TCr
-0.57%+1.27%-17.24%-34.99% 6.02TCr
-2.23%+5.48%+499.46%+29.31% 5.81TCr
-2.03%-2.62%-7.46%+27.87% 4.97TCr
-4.58%-2.73%+2.93%+157.71% 4.67TCr
-1.64%+1.07%+57.80%-17.34% 3.26TCr
-0.98%+1.91%+48.35%+95.93% 2.57TCr
-0.19%-4.74%+2.30%+196.81% 2.27TCr
-1.13%-2.45%+65.99%+110.75% 1.65TCr
Average -1.60%+0.17%+76.42%+71.86% 4.06TCr
Weighted average by Cap. -1.83%+0.82%+90.04%+44.75%

Financials

2026 *2027 *
Net sales 97Cr 83Cr 78Cr 71Cr 133.7Cr 9.13TCr 134.16Cr 924.13Cr 358.27Cr 4.68TCr 362.8Cr 354.88Cr 15TCr 156.21Cr 134.53Cr 126.37Cr 115.53Cr 216.15Cr 15TCr 216.9Cr 1.49TCr 579.21Cr 7.56TCr 586.54Cr 573.74Cr 24TCr
Net income -14Cr -12Cr -11Cr -10Cr -19Cr -1.33TCr -19Cr -134.22Cr -52Cr -679.55Cr -53Cr -52Cr -2.19TCr 26Cr 22Cr 21Cr 19Cr 35Cr 2.41TCr 35Cr 244.2Cr 95Cr 1.24TCr 96Cr 94Cr 3.99TCr
Net Debt -16Cr -13Cr -13Cr -12Cr -22Cr -1.48TCr -22Cr -149.66Cr -58Cr -757.72Cr -59Cr -57Cr -2.44TCr -44Cr -37Cr -35Cr -32Cr -60Cr -4.11TCr -60Cr -416.37Cr -161.42Cr -2.11TCr -163.46Cr -159.89Cr -6.8TCr
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,346
Date Price Change Volume
04/26/04 $206.68 -0.80% 4,38,242
03/26/03 $208.35 -0.75% 5,58,821
02/26/02 $209.92 +3.50% 6,08,189
01/26/01 $202.83 +2.17% 6,56,301
31/26/31 $198.52 -0.25% 5,03,716
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
206.68USD
Average target price
285.42USD
Spread / Average Target
+38.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock